·	Ç J					
Page 1 of 2 Page	ges [X] Origina	al [] Substitute	: [] Sup	plemental	Atty. Docke	et: GREGOR 2
Cor	nbined Declarat	ion for Patent	Applicati	on and Pov	ver of Atto	rney
My residence, pos and sole inventor the subject matter	inventor, I hereby declar t office address and citi- (if only one name is list which is claimed and fo Anti-Viral Drugs	zenship are as stated ted below) or an orig r which a patent is so	inal, first and ught on the in	joint inventor (i	if plural names	are listed below) of
Derivatives	Amp virai Diug	and Inaimac	tuncai Ci	mpositions	Containing	Tinazonunione
	which (check one)					
[X]	U.S. Appln. Nowas/will be filed in t (PCT) application, _]	he U.S. under 35 U.S PCT/II.2005/000335 *; national stage appl	.C. §371 by ea ; filed <u>24 Ma</u>	ntry into the U.S arch 2005, ent	ry requested on	
and was amended	on (include dates of amer	ndments under PCT Art.	19 and 34 if PC	(if applical	ble).	
amendment referre	nd understand the cont d to above; and I ackno material to patentability	wledge the duty to di	sclose to the			
	ign priority benefits und breeder's rights certific , listed below:					
	Application No.	Country		Filing Date (MM	(I DD YYYY)	
application designa	n priority above, I herekting a country other that the earliest application in Non-Priority Application N	an the United States) from which foreign pr	or for an involutionity is claim	entor's or plant b ned (if left blank,	oreeder's certific	ate, having a filing
_			· · · · · · · · · · · · · · · · · · ·			_

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional applications listed below:

Application No. Filing Date (MM DD YYYY)
60 555,667 03 24 2004

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application No. Filing Date (MM DD YYYY) Status (patented, pending, abandoned)
PCT/IL2005/000335 24 March 2005 Pending

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444, which is presently:

BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197

Page 2 of 2 Pages <u>Fitle: Screening of Anti-Viral Drugs and 1</u>	Pharmaceutic	al Con	nposi	tions		•	cket: GREGOR og Thiazolidin
<u>Derivatives</u>							
J.S. Application filed	, Serial No.						e ee
J.S. Application filed	, Serial No.	PCT	IL.200	5/00	0336		De la
The undersigned hereby authorizes the U.S. Attorneys of Ben-Ami & Associates as to any action to be taken in lirect communication between the U.S. Attorneys or Agwhom instructions may be taken, the U.S. Attorneys or A hereby further declare that all statements made her information and belief are believed to be true; and that tatements and the like so made are punishable by fine talse statements may jeopardize the validity of the application.	the U.S. Patent a gents and the und Agents appointed rein of my own nat these statem or imprisonmen	herein v knowled ents wer t, or bot	emark d. In t vill be dge ar e mad h, und	Office the ever so not true le wit er 18	e regardent of a tified became the tified to the the legal to the lega	ding the chang the y the u hat all knowle	is application with ge of the persons indersigned. Statements madedge that willful
		an issue	1 111616	2011 .			
FULL NAME OF FIRST INVENTOR	INVENTOR'S STO	TOM	and	4/	•		18-9-06
Paul GREGOR	your	Y	The	-		لـــــا	10 1-00
RESIDENCE		V	V		TIZENSI	IIP	
Rehovot, Israel	. 			Is	rael		
POST OFFICE ADDRESS							
7/1 Eizenberg Street, Rehovot 76291, Israel	· · · · · · · · · · · · · · · · · · ·						
FULL NAME OF SECOND JOINT INVENTOR	INVENTOR'S SIG	NATURE					18,9,00
Nicholas HARRIS <	1	-			··	اـــــــــــــــــــــــــــــــــــــ	10,1,0
RESIDENCE				- 1	TIZENSF	IIP	
Rehovot Israel				Is	rael		
POST OFFICE ADDRESS							
14/7 Hanassi Harishon Street, Rehovot 76302, Isr	The second secon						
FULL NAME OF FOURTH JOINT INVENTOR	INVENTOR'S SIG	NATURE	ZU			Ì	18-9-06
Regina ZHUK		/ <u>`</u>				i	10-1-00
RESIDENCE				1 .	TIZENSI:	ΠP	
Ness Ziona, Israel				Is	rael		
POST OFFICE ADDRESS							
14/11 Hatayassim Street, Ness Ziona 74062, Israe	1						
FULL NAME OF FIFTH JOINT INVENTOR	INVENTOR'S SIG	NATURE					DATE
RESIDENCE	<u> </u>			cr	TIZENSH	I ПР	
POST OFFICE ADDRESS						.	

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INTIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SEEN BY ALL INVENTORS.

INVENTOR'S SIGNATURE

DATE

CITIZENSHIP

FULL NAME OF SIXTH JOINT INVENTOR

RESIDENCE

POST OFFICE ADDRESS